secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001628280-24-012373
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics reports FY 2023 net loss of $71.9M; topline data expected Q4 2024 for Advance-HTN
--------------------------------------------------------------------------------

- Net loss of $71.9M for FY 2023 vs $29.8M in 2022; R&D expenses increased to $70.4M.
- Cash, cash equivalents and investments $239.0M at Dec 31, 2023; subsequent private placement raised ~$120M.
- Entered into ATM equity offering sales agreement to sell up to $100M of common stock.
- Pivotal Advance-HTN trial topline data expected Q4 2024; Launch-HTN data in 2H 2025.
- Explore-CKD Phase 2 trial design modified; topline data expected Q4 2024 to Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/0001628280-24-012373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000162828024012373/mlys-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer